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1. Introduction 
Ulcerative Colitis (UC) is a chronic inflammatory condition that frequently affects men and 
women of childbearing age. Concerns are often raised by both patients and clinicians 
regarding the effects of the disease and its treatments on reproduction and lactation. 
Many studies have examined fertility in UC patients in comparison with the general 
population. Most of these have not demonstrated a significant difference between the two 
groups. The observed decrease in fertility in some reports was largely attributable to patient 
choice, and the use of certain drugs such as sulfasalazine in men. Decreased fertility was 
also reported in women who have undergone surgery for their disease.  
Pregnancy is considered high risk in patients with UC. Numerous studies have described 
the obstetric and neonatal outcomes of these patients, and reported similar pregnancy 
outcomes in comparison to the general population. However some population-based studies 
have found an increased incidence of low birth weight and preterm delivery in UC patients. 
This observed difference seems to be mainly related to disease activity and severity during 
pregnancy and the appropriate treatment required. On the other hand pregnancy does not 
appear to increase the risk of disease relapse or severity. The course of UC during 
pregnancy is partly determined by its activity at conception. Therefore UC patients should 
be advised to attempt to conceive during periods of disease remission. 
Patients are often concerned about the safety of UC pharmacotherapy during pregnancy 
and lactation. Some patients choose to discontinue their maintenance therapy at least until 
the birth of their baby while others rely on their treating clinician to make the appropriate 
and safe decision regarding their treatment. Two issues have to be considered in this 
setting; first is the relative safety of the drug and secondly the benefit risk ratio of its use 
in pregnancy and lactation. A large amount of safety data is available on drugs that have 
been in use for decades, however modern medicine has witnessed the introduction of  
new therapeutic agents that have revolutionized the treatment of inflammatory diseases 
but there is limited data available regarding their safety during pregnancy and breast 
feeding. 
The topic of UC and pregnancy is quite complex involving a range of issues including the 
effects of both the disease and its treatment options on fertility, pregnancy and lactation, in 
addition to the effects of pregnancy and lactation on the course of the disease. The aim of 
this chapter is to review the available data and discuss this topic in more detail.  
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2. UC and fertility 
There are a number of considerations when discussing the relationship between UC and 
fertility including the effects of the disease and the medical and surgical management 
options on both male and female reproduction and the risk of infertility. Infertility is defined 
as failure to conceive after one year of regular unprotected intercourse.  
A number of studies have suggested that male fertility in UC is comparable to the general 
population. A survey of 62 men with UC and 140 controls found the number of pregnancies 
in the UC group was not statistically different to that in the control group. Fecundability 
(the probability of pregnancy per menstrual cycle with unprotected intercourse) was similar 
in the two groups [1]. A case control study of 1400 patients by Moody et al demonstrated no 
significant difference in the mean number of children born to male patients with UC 
compared to the general population [2].  
Fertility rates decline in male patients following ileal pouch anal anastomosis (IPAA) for 
UC. In a retrospective review of 111 patients by Heuting et al [3] the incidence of sexual 
dysfunction after IPAA was reported at 20%. A smaller prospective study of 18 patients by 
Berndtsson et al [4] showed loss of ejaculation in <5% of male patients following IPAA.  
However in both studies the patients reported overall satisfaction with their quality of life 
including overall sexual function following surgery. Gorgun et al assessed sexual function 
in 122 male patients who underwent IPAA between 1995 -2000 using the validated 
International Index of Erectile Function (IIEF) scoring instrument. This index scale examines 
sexual function in five categories: erectile function, orgasmic function, sexual desire, 
intercourse satisfaction and overall satisfaction. There was a statistically significant 
improvement in the scores of 4 categories following surgery with an increase in the mean 
erectile function score by 2.12 points (p=0.02) after IPAA [5]. 
Initial studies demonstrated infertility rates of up to 49% among women with UC, which is 
higher than documented for the general population (7%-12%)[6]. More recent studies have 
shown that female UC patients who have not had surgery have fertility rates comparable to 
the general population, and this largely reflects improvement in the medical management of 
UC over the years, leading to better control of disease activity, general health and 
reproductive function.  In a study comparing 290 women with UC to 661 non IBD controls, 
Olsen et al found equal fecundability ratios (FR=1.01) in the two groups, but FR dropped to 
0.02 (p<0.001) after IPAA, figure 1 demonstrates the results of the study [7]. Johnson et al 
confirmed these findings in a study showing 13.3% infertility rates in UC patients who are 
medically managed compared to 38.6% infertility rates in UC patients following IPAA, 
p<0.001 [8].  
2.1 Drugs used for UC and fertility 
Medical management of UC involves the use of a range of pharmacological agents with 
variable effects on fertility in males and females. Sulphasalazines and 5-aminosalicylates 
(5ASA) are often used for maintenance of disease remission in UC. Both rat and human 
studies have demonstrated reduced male fertility during the use of sulphasalazine due to its 
adverse effects on sperm count, morphology and motility. These effects are secondary to the 
non-therapeutic sulphapyridine moiety and are completely reversible on cessation of the 
drug [9,10], or replacing it with a different 5ASA [11]. There are no reports of reduced 
female fertility with the use of sulphasalazine.  
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Corticosteroids are used to induce remission during exacerbations of UC. They have been 
shown in rat studies to depress serum testosterone levels, but have no effect on 
gonadotropin levels [12]. Serum testosterone levels returned to normal on withdrawal of 
steroid treatment. Lerman et al demonstrated similar effects on fertility in male rats, 
although no change was seen in sperm number and motility [13]. There is limited data on 
the effects of exogenous steroids on male fertility in humans. A study by Roberts et al, 
suggested that an increase in endogenous cortisol levels observed following strenuous 
exercise was associated with a subsequent decrease in sperm concentration [14].  Therefore, 
steroids should only be used short term to control disease activity. The use of steroids for 
different diseases in females has not been associated with impaired fertility. 
 
 
Fig. 1. Fecundability ratio in patients with ulcerative colitis before and after diagnosis, and 
after ileal pouch anal anastomosis compared with healthy controls. Reprinted from Olsen 
and colleagues [7] 
Immunosuppressants are frequently used in the management of UC as steroid-sparing 
drugs to maintain disease remission. Their effects on male fertility in humans are 
controversial. Although the use of Mercaptopurine  (MP) in male mice has been associated 
with reduce fertility [15], it has not been shown to affect sperm count or quality [16]. 
Francella et al, in a retrospective review of 485 IBD male and female patients found that the 
use of MP did not result in a statistically significant difference in conception failure 
compared to IBD patients not receiving MP [17]. Review of the long-term use of 
immunosuppressants such as Azathioprine in renal transplant patients has also shown no 
obvious effects on fertility in both males and females [18].   
The use of anti-TNFα agents in the management of UC has been increasing over the last 
decade with accumulating evidence to support its beneficial effects. There are no human 
data on the effects of biologic therapy on fertility but data on its safety during pregnancy is 
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increasing (this will be discussed in more detail later). Animal studies have demonstrated no 
adverse effects on both male and female fertility [19]. 
3. UC and pregnancy 
3.1 The effects of UC on pregnancy 
Pregnancy is considered high risk in patients with UC, and this is primarily related to 
disease activity at conception and during pregnancy. The overall outcome of pregnancy in 
UC is comparable to the general population however active disease during pregnancy 
especially when severe results in adverse pregnancy outcomes.  This has been confirmed by 
a number of studies. A Danish population based study demonstrated no increased risk of 
low birth weight and intrauterine growth retardation in patients with UC, however the risk 
of preterm delivery was increased when the first hospitalization for UC took place during 
pregnancy (odds ratio = 3.4, 95% confidence interval = 1.8-6.4) [20]. A retrospective review 
of 98 pregnancies in IBD patients by Federkow et al, found a statistically significant higher 
rate of preterm delivery (p < 0.01) than the rate of the control group. The risk was further 
increased when a disease exacerbation occurred during pregnancy [21].  Bush et al, in a case 
control study of 116 pregnancies in IBD patients demonstrated an increased risk of low birth 
weight in the UC group compared to the Crohn’s disease (CD) group (19% vs. 0%, p = 
0.002), with flares during pregnancy associated with an increased risk for preterm delivery 
(27% vs. 8%, p = 0.02) and LBW (32% vs. 3%, p = 0.003) [22]. A population based cohort 
study of 239773 pregnant women including 756 women with IBD, by Kornfeld et al, 
supported the increased risk of adverse pregnancy outcomes such as preterm delivery, low 
birth weight, small for gestational age, and cesarean section in pregnant women with IBD 
[23].  Therefore control of disease activity during pregnancy is imperative for the well being 
of the mother and the baby. 
3.2 The effects of pregnancy on UC 
Pregnancy was initially thought to lead to improved control of disease activity during the 
gestational period as a result of the relative suppression of the mother’s immune system to 
allow fetal development. However, evidence suggests that gestational disease activity is 
influenced by factors other than the physiological state of pregnancy. Disease activity 
during pregnancy is determined by activity at conception. Patients who conceive during 
disease remission have relapse rates comparable to non-pregnant UC patients over a nine-
month period, with 70-80% of these patients remaining in remission throughout the 
gestational period [24]. If an exacerbation occurs it is likely to be mild and responsive to 
medical treatment. In patients with active disease at conception, about 45% will 
deteriorate, 25% will improve and 25% will remain unchanged, therefore about 3 out of 4 
will have active disease during their pregnancy, resulting in adverse perinatal outcomes 
[24]. 
The risk of postpartum disease relapse is partly determined by disease activity at the time of 
delivery. In a study of 324 patients, Modagam et al demonstrated that only 13% of 
patients with quiescent to mild disease at term experienced a flare in the puerperal period 
in contrast to 53% of patients with active disease at delivery [25]. However, there is 
evidence suggesting that pregnancy itself leads to improved control of IBD activity in the 
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years following it. Castiglione et al reported reduced rates of disease relapse in the first 
three years after pregnancy compared to the pre-pregnancy period in UC patients 
(p<0.005) [26]. 
Pregnancy is safe in patients with IPAA but impaired pouch function can be experienced 
during pregnancy with increased daytime and nocturnal stool frequency and incontinence. 
However, pouch function tends to return to pre-pregnancy function following delivery 
[27].   
3.3 Mode of delivery in UC 
The observed rates of caesarean section in UC is higher than the general population [27]. 
The reason for this is unknown. The decision to proceed to cesarean section should be made 
purely on obstetric grounds except in cases where the patient has undergone IPAA. Such 
patients can have normal vaginal deliveries without damaging the pouch [28], however 
there is concern for damage to the anal sphincter. The risk of anal sphincter damage is 
compounded by aging, therefore the effects may not become apparent for several years. 
Although the current reports of IPAA patients who have had vaginal deliveries demonstrate 
no irreversible pouch complications in the majority of patients, there is no long-term follow-
up data available (i.e. 20-30 years). Therefore, the decision on mode of delivery in IPAA 
patients should be made following detailed discussion of the potential effects on pouch and 
anal function by the patient, obstetrician and colorectal surgeon.      
3.4 Medications for the treatment in UC and pregnancy 
Patients are often concerned about the potential teratogenecity of the drugs used in UC and 
may even opt to discontinue their maintenance therapy during pregnancy. Experience and 
data support the safe use of many maintenance drugs during pregnancy. In fact, disease 
relapses and continued disease activity during pregnancy as a result of either cessation of 
maintenance therapy or/and avoiding induction therapy are more harmful to both the 
mother and the unborn baby [29]. Patients should be counseled prior to pregnancy 
regarding the potential toxicity of some of their medications, however they should be 
advised to maintain safe medical treatment for adequate control of disease activity during 
pregnancy. The risk of maternal drug exposure to fetal development is classified by the 
Food and Drug Administration (FDA) into categories, see table 1. The FDA pregnancy 
categories of drugs used in UC are summarized in table 2. 
5 Aminosalicylates & sulphasalazine 
5 ASA preparations are frequently used as first line maintenance therapy for UC. They have 
been in use for decades with numerous studies supporting their safe use in pregnant 
patients. The FDA currently classifies them as pregnancy category B. Although 5 ASAs are 
poorly absorbed from the gastrointestinal tract, they do cross the placenta once they reach 
systemic circulation [30]. No consistent teratogenic effect has been demonstrated in animal 
and human studies. In a prospective cohort study of 60 pregnant IBD patients, Norgard et al 
found no substantial increased risk of malformations in patients who received 5ASAs 
during the first trimester of pregnancy, odds ratio 1.9 (95% confidence interval 0.7-5.4) [31], 
but observed an increased risk of stillbirths and preterm deliveries which could be due to 
the disease rather than the drugs as the controls used were women without IBD. A meta-
analysis of 7 studies, that included 2200 pregnant women with IBD; 642 received 5-ASA 
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drugs (mesalazine, sulfasalazine or olsalazine) and 1158 received no medication, suggested 
only a 1.16-fold increase in congenital malformations, a 2.38-fold increase in stillbirth, a 1.14-
fold increase in spontaneous abortion, a 1.35-fold increase in preterm delivery, and a 0.93-
fold increase in low birth weight [32].  
 
FDA Pharmaceutical Pregnancy Categories 
Pregnancy 
Category 
A 
Adequate and well-controlled human studies have failed to demonstrate a risk 
to the fetus in the first trimester of pregnancy (and there is no evidence of risk 
in later trimesters). 
Pregnancy 
Category 
B 
Animal reproduction studies have failed to demonstrate a risk to the fetus and 
there are no adequate and well-controlled studies in pregnant women OR 
Animal studies have shown an adverse effect, but adequate and well-
controlled studies in pregnant women have failed to demonstrate a risk to the 
fetus in any trimester. 
Pregnancy 
Category 
C 
Animal reproduction studies have shown an adverse effect on the fetus and there 
are no adequate and well-controlled studies in humans, but potential benefits 
may warrant use of the drug in pregnant women despite potential risks. 
Pregnancy 
Category 
D 
There is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience or studies in humans, but potential 
benefits may warrant use of the drug in pregnant women despite potential risks. 
Pregnancy 
Category 
X 
Studies in animals or humans have demonstrated fetal abnormalities and/or 
there is positive evidence of human fetal risk based on adverse reaction data 
from investigational or marketing experience, and the risks involved in use of 
the drug in pregnant women clearly outweigh potential benefits. 
Table 1. FDA drug category during pregnancy 
 
FDA B FDA C FDA D FDA X 
5 ASAs 
Amoxicillin/ Clav 
Metronidazole 
Infliximab 
Adalimumab 
Corticosteroids 
Ciprofloxacin 
Cyclosporin 
Loperamide 
Azathioprine 
Mercaptopurine 
Lomotil 
Methotrexate 
Table 2. FDA pregnancy category of drugs used for UC 
Sulfasalazine was initially thought to be teratogenic, however more recent studies failed to 
identify significant association between the drug and congenital anomalies [33, 34]. 
Sulfasalazine interacts with the cell membrane transporter for natural folates and interferes 
with folate absorption, which in turn may lead to folate deficiency with increased risk of 
neural tube defects and cardiovascular defects [35, 36]. Therefore folate supplementation 
with up to 2mg of folic acid daily should be strongly recommended to female patients on 
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sulfalazine even prior to pregnancy [37]. Alternatively, patients could be switched to 
mesalamine, but they should still be advised to take 400micrograms of folic acid daily when 
planning to conceive.  
Corticosteroids 
Corticosteroids are indicated for induction of disease remission during exacerbations of UC. 
The FDA classifies them as pregnancy category C. Their use in pregnancy has been 
associated with increased risk of cleft palate in a number of case control studies [38, 39]. In a 
prospective control study of 311 pregnant IBD patients, Gur et al found no significant 
difference in the rate of major anomalies between the group treated with corticosteroids 
(GCS) during pregnancy compared to the control group [12/262 = 4.6% (GCS), 19/728 = 
2.6% (control), [P = 0.116]. There was no case of oral cleft and no pattern of anomalies 
among the GCS exposed group [40]. 
Corticosteroids can cross the placenta but the rate varies with the type of steroid depending 
on the extent of placental metabolism and placental and albumin binding affinity [41]. Fetal 
exposure to prednisolone is lower than for other steroids such as dexamethasone, and 
should therefore be used in preference to them during pregnancy [42, 43]. 
Immunosuppressants 
Escalation of maintenance medical treatment to immunosuppressants is required in patients 
with moderate to severe refractory UC. This category includes azathioprine (AZA), 
mercaptopurines (MP), and methotrexate (MTX). The first two drugs are classified by the 
FDA as category D drugs, but MTX is classified as category X, and patients should be 
advised not to conceive on the drug or even within 3 months of stopping it, as it is 
associated with a high risk of developing craniofacial deformities, limb defects and severe 
central nervous system abnormalities [44]. 
AZA/MP are relatively less toxic during pregnancy in humans although animal studies 
have demonstrated an increased risk of teratogenecity with their use [15]. The oral 
bioavailability of the two drugs is low (47% for AZA and 16% for MP)(44), and their 
placental transfer is limited [45]. AZA/MP are absorbed in their inactive form and the fetal 
liver lacks the enzyme necessary to convert them to the active and potentially toxic 
metabolites [46]. Case reports of the teratogenic effects of AZA use during pregnancy such 
as chromosomal abnormalities and myelotoxicity in the infant originate from transplant and 
oncology patients using higher doses of the drug than would be used in UC [47]. AZA is 
used at a dose of 1-1.5mg/kg of body weight in patients with UC, and studies on its effects 
during pregnancy at this dose have found no increased risk of teratogenicity [48- 50]. In a 
large retrospective review of 325 pregnancies, Francella et al showed that the use of AZA/ 
MP prior to, at conception and during pregnancy does not increase the risk of spontaneous 
abortions, stillbirths, prematurity or the rate of neonatal or childhood infections [17]. Shim et 
al reported the safe use of AZA /MP in pregnant IBD patients in Australia.  In 19 births 
exposed to AZA /MP there was 1 neonatal adverse outcome in the exposed group as 
compared to 4 in controls (5.3% vs. 5.4%, p=0.97). One congenital anomaly was seen in each 
group (p=0.27). No low birth weight at term was seen in either group. Placental blood flow in 
4 women exposed to AZA /MP was normal [51]. In a large cohort from the CESAME study, 
Coelho et al found no significant difference in overall pregnancy outcomes between 
pregnancies exposed to thiopurines (n=86) and those not exposed to any treatment (n=45) [52]. 
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Cyclosporin (CYA) is indicated in patients with fulminant colitis or severe exacerbations 
of UC unresponsive to induction therapy with steroids. It is classified as FDA category C. 
It is only 34% absorbed from the gastrointestinal tract, but can cross the placenta [53]. 
Animal studies found some fetal toxicity associated with exposure to the drug at 
maternotoxic doses including embryo lethality, and reduced fetal growth [54]. Reports of 
its use in humans during pregnancy come from transplant patients. A meta-analysis of 15 
studies that included 410 patients failed to identify any significant teratogenicity 
associated with the use of CYA. The rates of prematurity and low birth weight were 
higher in infants exposed to CYA, but did not reach statistical significance [55]. In cases of 
fulminant colitis the use of CYA may preclude the need for colectomy. Colectomy 
resulted in fetal loss in 2 of 4 pregnant patients who underwent surgery for fulminant 
colitis in a case series by Anderson et al [56]. 
Biologic agents 
Anti TNFα therapy was initially used in refractory and fistulating CD, but there is 
increasing evidence to support its use in UC. Naturally there were numerous concerns for 
their potential toxicity in pregnancy, however recent studies have demonstrated their safety 
during pregnancy. A case series of 4 pregnant IBD patients who continued their infliximab 
(IFX) treatment during pregnancy by Zolinkova et al, reported therapeutic IFX levels in the 
cord blood of 3 babies at levels 2-3 fold higher than in the peripheral blood of the their 
mothers, and during the 3- to 6-month follow-up, the children developed normally without 
signs of infections or allergic reactions, and had normal antibody titres after routine 
childhood vaccinations [57]. A larger observational study by Schnitzler et al, assessed 212 
IBD patients on anti TNFα treatment and found that 32 of the 42 pregnancies ended in live 
births with a median gestational age of 38 weeks (interquartile range [IQR] 37-39). There 
were seven premature deliveries, six children had low birth weight, and there was one 
stillbirth. One boy weighed 1640 g delivered at week 33, died at age 13 days secondary to 
necrotizing enterocolitis. A total of eight abortions (one patient wish) occurred in seven 
women. Trisomy 18 was diagnosed in one foetus of a mother with CD at age 37 years under 
adalimumab (ADA) treatment (40 mg weekly) and pregnancy was terminated. Pregnancy 
outcomes after direct exposure to anti-TNFα treatment were not different from those in 
pregnancies before anti-TNFα treatment or with indirect exposure to anti-TNFα treatment 
but outcomes were worse than in pregnancies before IBD diagnosis [58]. Anti TNFα drugs 
are classified as pregnancy category B by the FDA. 
Although data supports the safe use of biologic therapy in UC patients during pregnancy, 
we must be aware of the potential complications of immunosuppression in babies born to 
mothers receiving anti TNFα treatment during the third trimester of pregnancy. Cheent et al 
reported a case of an infant born to a mother who received IFX throughout her pregnancy, 
dying of disseminated TB infection at age 4.5 months after receiving BCG vaccination at the 
age of 3 months. Live attenuated vaccines including BCG are contraindicated in individuals 
who are receiving immunosuppressive drugs, and physicians should exercise caution before 
such vaccines are used in infants born to mothers taking anti-TNF therapies or other 
potentially immunosuppressive IgG1 antibodies [59]. Consideration should be given to the 
cessation of biologic treatment in the third trimester of pregnancy to reduce foetal exposure 
to the drug immediately prior to delivery.  
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Antibiotics 
Antibiotics such as metronidazole and ciprofloxacin have limited use in UC. Their short-
term use for the treatment of pouchitis post IPAA is considered low risk in pregnancy. 
Metronidazole is classified as FDA pregnancy category B. Its use in pregnancy has not been 
associated with increased risk of congenital abnormalities. A retrospective review by 
Sorensen et al demonstrated no increased preterm delivery following metronidazole 
treatment during pregnancy in a cohort of 124 patients [60]. Diav-Citrin et al prospective 
studied 228 women exposed to metronidazole during pregnancy and found no significant 
difference between the cases and controls in terms of congenital abnormalities and preterm 
delivery, however the mean birth weight was lower in the treatment group [61]. 
Amoxicillin/ clavulanic acid is an FDA category B drug and is considered safe during 
pregnancy. 
Ciprofloxacin and other quinolones are classified as FDA pregnancy category C drugs. In a 
prospective review of 200 patients treated with quinolones during pregnancy, Loebstein et 
al failed to show an increased risk of arthropathy demonstrated in animal studies [62]. There 
was no significant increased rate of spontaneous abortions, prematurity or birth weight in 
the treatment group.  Sulphonamides and tetracyclines are contraindicated in pregnancy. 
Anti-diarrheals 
Anti-diarrheal agents are used for symptomatic relief during pregnancy. Loperamide is 
classified as FDA category B drug. In a prospective case control study of 105 women, 
Einarson et al found no increased risk of miscarriage, preterm delivery or congenital 
anomalies with the use of loperamide intermittently during pregnancy [63]. However, a 
Lower mean birth weight was documented in infants whose mothers received loperamide 
continuously during pregnancy. Another study of 638 pregnancies exposed to loperamide 
from early pregnancy showed an increased rate of congenital defects (OR 1.41; 97% CI 1.03 – 
1.93); only hypospadias showed a significant increase (RR=3.2, 95% CI 1.3 – 6.6) [64]. 
Lomotil (diphenoxylate hydrochloride/atropine) is classified as FDA category C drug. It 
should be used with caution in pregnant patients, as it is not known whether it can cross the 
placenta.  
4. UC and breastfeeding 
Breastfeeding has well-recognized benefits to infants, including reducing the risk of 
developing IBD in later life [65]. It has not been shown to influence the pattern of UC 
disease activity in the post partum period [66]. However, patients are often concerned about 
the potential toxicity of pharmacological UC therapy to the breastfed infant. Patients should 
be offered individual advice regarding whether or not to breastfeed depending on the 
benefit/ risk ratio of the prescribed medication on the infant, and the risk of cessation of 
medical therapy to the mother. 
Sulphasalazine and other 5ASAs are relatively safe during breastfeeding as less than 10% of 
the maternal dose is excreted in breast milk [67], however there are two case reports in the 
literature describing diarrhea in a breastfed infant whose mother was being treated with 
sulphasalazine [68, 69]. There are no other studies demonstrating adverse effects of 5ASAs 
on breastfed infants, therefore UC patients should be encouraged to breastfeed while on 
aminosalicylates.  
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Only 5 - 25 % of maternal plasma steroid concentrations are present in breast milk [70], 
therefore infant exposure to the drug is very low. There are no reports of harmful effects on 
infants breastfed by mothers taking corticosteroids, however patients should be advised to 
delay breastfeeding by 4 hours following administration of steroids to decrease infant 
exposure to the drug since its half life is 3 hours [71].  
Immunosuppressants are secreted in breast milk and can potentially suppress the infant’s 
immune system. Clinical experience suggests that AZA and MP are safe to use while 
breastfeeding. In a retrospective review of nursing mothers taking AZA, Angelberger et al 
demonstrated that the infants had age appropriate mental status and physical development 
compared to the control group with no difference in the rate of hospitalization [72]. CYA 
and MTX should be avoided by nursing mothers due to the risk of infant 
immunosuppression, potential harmful effects on growth, and association with 
carcinogenesis [73]. There is limited data describing the use of biologic drugs during 
lactation. In a small case series of 3 mothers treated with IFX during the post partum period, 
Kane et al found no detectable levels of IFX in the breast milk or the sera of the breastfed 
infants [74]. This suggests that mothers on IFX should not be discouraged from 
breastfeeding. It is not known whether ADA is secreted in breast milk and should therefore 
be avoided in nursing mothers.  
Amoxicillin/ clavulanic acid is safe to use in nursing mothers [75], however there is limited 
data regarding metronidazole and ciprofloxacin, and they should be avoided during 
breastfeeding. Loperamide and diphenoxylate hydrochloride are excreted in breast milk and 
should be avoided in nursing mothers [70]. See table 3 for the summary of drug safety 
during breastfeeding. 
 
Low risk Limited data Not recommended Contraindicated 
Steroids 
Mesalamine 
Sulphasalazine 
Amoxicillin/ 
clavulanic acid 
Adalimumab 
Infliximab 
Metronidazole 
Ciprofloxacin 
Azathioprine 
Mercaptopurine 
Methotrexate 
Cyclosporin 
Table 3. Safety of drugs during breastfeeding 
5. Summary 
Patients with UC should be reassured that the diagnosis of UC does not necessarily imply 
impaired fertility and/or increased risk of congenital and developmental abnormalities in 
the baby. Impaired fertility is related to disease activity, pharmacological agents used for 
medical management, and/or surgery for UC (IPAA). Active UC at conception is associated 
with increased risk of gestational disease activity and exacerbations, which in turn is 
associated with increased risk of adverse pregnancy outcomes. Although certain drugs 
used for the treatment of UC such as MTX are potentially teratogenic and are 
contraindicated prior to and during pregnancy, the majority of them are relatively safe, 
including immunosuppressants and biologic agents. Clinical experience has demonstrated 
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that disease activity during pregnancy is more harmful to both the mother and the baby 
than the majority of drugs used to treat exacerbations, and /or maintain remission of UC 
during pregnancy.  
UC patients should be advised to attempt to conceive during periods of disease remission. 
The potential toxicity of medical treatment in pregnancy should be discussed, and the 
benefit / risk ratio estimated on an individual basis.  
UC patients should not be discouraged from breastfeeding their infants, however the 
potential toxicity of the mother’s medications should be taken into consideration and the 
risk to the baby weighed against the risk of disease relapse in the mother if medical 
treatment was discontinued.  
6. Expert opinion 
The second European evidence-based consensus on the diagnosis and management of 
inflammatory bowel disease (IBD) published the following statements in relation to IBD and 
pregnancy [76]: 
IBD and fertility: 
• IBD does not seem to affect fertility when the disease is inactive, however disease 
activity leads to reduced fertility. 
• Female patients who undergo surgery are at risk of impaired tubal function. 
• In male patients rectal excision may cause impotence of ejaculatory problems, however 
there is no comparison with the general population. 
• Sulphasalazine therapy causes reversible infertility in male patients because of changes 
in semen quality. 
IBD and pregnancy: 
• It is advisable to strive for clinical remission before conception. 
• If conception occurs at a time of quiescent disease the risk of relapse is the same as on 
non-pregnant women. 
• If conception occurs at a time of disease activity, two thirds have persistent activity, and 
of these two thirds deteriorate. 
• Flares are best treated aggressively to prevent complications. 
• Insufficient data exists about maternal morbidity and fetal mortality at surgery. 
• Both clinical activity and surgical intervention decline with pregnancy and parity. 
Mode of delivery: 
• The mode of delivery should primarily be governed by obstetric necessity and indication, 
but also in conjunction with the gastroenterologist and/or colorectal surgeon.  
• An ileo-anal pouch is regarded as an indication for caesarean section. 
• Colostomy or ileostomy patients can deliver vaginally. 
Medical treatment during pregnancy: 
• Medical treatment for IBD should generally continue during pregnancy, because the 
benefits outweigh the risk of medication. 
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